Meeting
2020 ASCO Virtual Scientific Program
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.
Authors
M. Andres Cuellar
Catalan Institute of Oncology, Barcelona, Spain
M. Andres Cuellar , Ana Medina , Regina Girones , B.P. Valderrama , Albert Font , MJ Juan-fita , Guillermo de Velasco , Ferran Ferrer , Francesc Vigués , Xavier Garcia del Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03702179
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5097)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5097
Abstract #
TPS5097
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande
Poster
2019 ASCO Annual Meeting
A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).
First Author: Viktor Grünwald
Poster
2019 ASCO Annual Meeting
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
First Author: Taofeek Kunle Owonikoko
Poster
2019 ASCO Annual Meeting
A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.
First Author: Maria M Rubinstein